Cerebrovascular events in IBD patients
Introduction
Inflammatory bowel disease [IBD] is considered an independent risk factor for thrombosis. Prevalence of thromboembolic events [arterial or venous thrombosis] in IBD is reported between 1.3-6.0%, with a 1.5-3.6-fold increased risk compared with the general population and other inflammatory disorders. 1, 2, 3 This risk reaches 15-fold when referring to active IBD. 4 Cerebrovascular accidents [CVA] are infrequently reported in IBD patients, mostly in the form of a single case report or small series 5, 6, 7, 8, 9 with a reported overall prevalence of 0.12-4%. 2 Anti-tumour necrosis factor alpha [anti-TNF alpha] agents revolutionised IBD treatment. Infliximab and adalimumab are globally approved for the treatment of moderate to severe IBD. 10 However, their long-term use has been associated with several neurological complications, primarily demyelinating and septic disorders. 11, 12 The association, if any, of anti-TNF alpha with CVA is hitherto unknown. This knowledge gap hampers the ability for rational decision making in patients who develop or are at risk of developing CVA while receiving anti-TNF alpha treatment.
We therefore set out to describe a series of IBD patients presenting with a CVA during anti-TNF alpha treatment, and to try to elucidate the impact of anti-TNF alpha resumption in these cases.
Materials and Methods

Study design
This European Crohn's and Colitis Organisation [ECCO] observational multicentre study retrospectively collected cases across the world through the CONFER [COllaborative Network For Exceptionally Rare case reports] project. The CONFER project was initiated by ECCO in order to specifically identify and report together rare IBD disease associations, which otherwise seldom get reported due to their exceptional rarity. Briefly, the CONFER methodology comprised selecting a topic worthy of investigation out of case proposals submitted by ECCO members. Once a specific IBD disease association was selected by a steering committee as a CONFER project [CVA in IBD patients under antiTNF alpha therapy in the case of the present manuscript], ECCO launched a call to identify similar cases encountered by IBD physicians worldwide.
The call to physicians was made through announcements in the ECCO annual congress and in national IBD meetings across Europe and during two international IBD meetings [the Falk symposium in London 2013 and the Ferring symposium in Prague 2013]. In addition, the call for similar cases was disseminated by direct emails to all ECCO members and affiliated physicians and in the ECCO website and eNews. Physicians were then prompted to report their case to the CONFER database using a pre-determined standardised case report form (CRF). The call for the present case series was entitled 'Have you encountered a case of CVA in an IBD patient associated or not with anti-TNF alpha therapy?'
Patients and procedures
Adult IBD patients having a CVA while receiving anti-TNF alpha therapy were eligible for inclusion in this study. Data were collected by a CRF, which was divided into two main sections. Section 1 included patient [epidemiological data, past history] and disease (date and summary of IBD diagnosis, Montreal classification, presence and summary of extra-intestinal manifestations, anti-neutrophil cytoplasmic antibody [ANCA] or anti-Saccharomyces cerevisiae antibody [ASCA] positivity, prior IBD treatment with particular interest in duration and reason for discontinuation, and prior surgery for IBD) characteristics.
Section 2 was dedicated to description of the event. Symptoms and findings of the neurological examination were registered, including level of consciousness, speech abnormalities, visual fields defects, oculomotor disorders, abnormalities in the rest of the cranial nerves, muscle tone/ strength change, presence of pyramidal or extrapyramidal signs, sensory abnormalities, signs of cerebellar deficits, gait changes, asymmetrical tendon reflexes, and urinary and/or fecal incontinence. Relevant laboratory tests as well as appropriate imaging and clinical work-up [including neuroradiological interventions] were also recorded.
CVA was defined as any ischaemic [thrombotic or embolic] or haemorrhagic [subarachnoid or intracerebral] stroke or any transient ischaemic attack. 13 CVA was judged as mild, moderate, or severe according to the consulting neurologist's decision. Event outcome was addressed at the time of report as ongoing or as having had a complete, minor, or major recovery, fatal outcome or an unknown course, again based on the neurologist's consultation. Special interest was given to whether anti-TNF alpha therapy was discontinued due to the event and whether it was re-introduced later on. Finally, a relationship between the CVA and the above-mentioned IBD regimens or other concomitant medication or comorbidities was investigated as impossible, possible, or probable, as per the treating physician's judgment. [either azathioprine/mercaptopurine or methotrexate] prior to CVA and all had received at least one course of corticosteroids since IBD diagnosis. The most common reason for IMS discontinuation was an adverse event in nine patients, whereas in five the treatment was still ongoing at the time of the event.
Results
Patients' background information
Regarding anti-TNF alpha therapy, eight patients were treated with infliximab only, four with adalimumab only, four with both agents, and three with certolizumab pegol as a third-line agent. At the onset of CVA, eight patients were receiving the anti-TNF alpha agent as monotherapy, six as combination therapy with corticosteroids, three as combination therapy with methotrexate, and two as triple combination therapy with corticosteroids and azathioprine. The duration of treatment until CVA onset was variable and averaged 11. 
CVA characteristics and outcome
CVA characteristics for the 19 patients are shown in Table 2 . Symptoms and signs were diverse, with 10/19 patients presenting with hemiparesis and seven with visual disturbances. Dysarthria, numbness, perioral paraesthesia, ataxia, headache, vomiting, coordination deficits, loss of consciousness, grand mal epilepsy, and bilateral choreoathetoid movements were also reported. Complete blood count and C-reactive protein were normal in the majority of patients. Electrocardiography and Holter monitoring were normal in all patients who underwent these studies, whereas echocardiography showed patent foramen ovale in three patients. Brain computed tomographic or magnetic resonance imaging and angiography were either normal or demonstrated diverse findings [ Table 2 ]. Coagulopathy tests conducted in 12 patients revealed factor V [Leiden] deficiency, hyperfibrinogenaemia, and hyperhomocysteinaemia in one patient each, whereas results were normal in nine.
CVA severity was judged as serious in 11 patients, moderate in three and mild in five. Recovery was complete in 16 patients, major in one and minor in two at last follow-up [ Table 2 ].
IMS was discontinued in six and anti-TNF alpha was withheld in all but three patients due to the CVA. Anti-TNF alpha therapy was re-introduced at the regular dosing protocol after CVA resolution in six patients and at an intensified dosing schedule in two, and none of these patients experienced a new episode of CVA or neurological deterioration over a mean follow-up of 39.8 months [median: 37.8, range: 5.6-98.2]. Anti-TNF alpha was not re-introduced in the remaining patients due to IBD remission in two, introduction of ustekinumab in one, methotrexate-induced clinical remission in one, colectomy in one, physician's concern regarding new central nervous system symptoms in one, and vasculitis in two for whom the biological was suspected to be the triggering factor. Relationship between the occurrence of the CVA and the IMS was judged by the treating physician as impossible in 11 patients and as possible in five, and between the CVA and the anti-TNF alpha therapy as impossible in three, as possible in 11, and as probable in five. Finally, six participants indicated a possible and two a probable relationship of the event with comorbidities.
Discussion
The present study describes a series of IBD patients affected by a CVA while being treated with an anti-TNF alpha agent. Twelve patients had received only one anti-TNF alpha agent at the time of the event, whereas seven had received at least one other anti-TNF alpha agent before the index one, without any prior CVA. The vast majority [17/19] were also treated with an IMS either simultaneously or prior to the event. Importantly, neurological recovery was complete in 16 patients. Moreover, anti-TNF alpha was re-introduced in eight patients and continued un-interrupted in another three without any seeming consequence in the form of recurrent CVA or deterioration of neurological status. Notably, this is, to our knowledge, the largest described series of IBD patients exhibiting a CVA while receiving anti-TNF alpha therapy.
Neurological complications in IBD patients are not infrequent but are poorly recognised and under-reported. CVA are even more rare, with cerebral infarction, TIA, and cerebral venous thrombosis being most frequently reported. 14, 15 IBD is reported as the leading underlying condition in 1-6% of cerebral venous thrombosis incidents, in many of these cases not temporally associated with an IBD flare. 15 Vasculitis, carotid arterial thrombosis, or thromboembolism, retinal branch artery occlusion, and paradoxical embolism are also reported as underlying CVA causes. 16 It is unclear whether arterial or venous infarcts are more prevalent. However, cerebral arterial thrombotic events were more common in a recent population-based study. 17 Our patients exhibited both venous and arterial events.
A recent meta-analysis showed that IBD is associated with an increased, albeit small, risk of CVA (odds ratio [ 20 Our patients were equally distributed among genders but manifested the CVA at a younger mean age [47 years] than the general population. Another population-based study indicated that a higher risk for cerebral arterial thromboembolic disease was associated only with CD (incidence rate ratio [IRR] 1.32; 95% CI,] 1.05-1.66). 21 This may seem to be in accordance with our group of patients, in whom the majority have had CD [14/19, 73 .6%]. However, inference is impossible, as our patients were selected by anti-TNF alpha treatment, which is more commonly administered to CD patients.
Peripheral neuritis and demyelinating disorders [multiple sclerosis and optical neuritis] are the most frequently reported neurological adverse events in patients receiving anti-TNF alpha treatment. 22, 23 A Food and Drug Administration-supported study reported 772 distinct neurological adverse events secondary to anti-TNF alpha agent exposure over a 10-year period. 24 However, the occurrence of CVA in IBD patients receiving anti-TNF alpha agents has been scantily studied and reported.
Our case series demonstrated that CVA do occur in this subgroup of anti-TNF alpha-treated IBD patients, which warrants prompt recognition and evaluation, although the majority of our patients recovered without significant neurological sequelae. CVA occurred early after anti-TNF alpha initiation in some patients. However, this could reflect the CVA being temporally related to a more active phase of disease than to the introduction of the anti-TNF alpha agent [ Figure 1 ]. Moreover, in 7/19 of the patients, CVA occurred after neurologically uneventful treatment with one or two other anti-TNF alpha agents prior to the index agent. Taken together with the fact that IBD itself may predispose at least to some forms of CVA, and that a proportion of patients exhibited additional risk factors for a CVA [ie smoking], the present observations may argue against a causal relation between the anti-TNF alpha agent and the CVA. Moreover, these findings could indicate that anti-TNF alpha may be safely resumed or continued in such patients, which may be important for patients who are dependent on anti-TNF alpha for IBD control. Nonetheless, these contentions should be perceived preliminarily and adopted with great caution, given the limited number of patients in this study, the retrospective nature of data collection, and the fact that the study was not designed to assess the incidence of CVA during anti-TNF alpha treatment compared with its incidence without these agents, nor whether anti-TNF alpha treatment modifies stroke incidence or severity in IBD patients. Physicians must exhibit increased vigilance when confronted with the occurrence of a CVA in an IBD patient under anti-TNF alpha therapy, and should explore further therapeutic options on a strict case-by-case basis, also keeping in mind potential non-medical consequences of their decision.
It should be noted that the outcome of CVA in our anti-TNF alpha-treated IBD patients seems no worse than the outcome of CVA in IBD patients not treated by anti-TNF alpha, based purely on clinical and imaging assessment, as described recently in a review of published case reports.
14 However, there are obvious methodological caveats limiting a direct comparison. Studies in patients with rheumatoid arthritis and plaque psoriasis have produced conflicting results, either favouring the occurrence of thromboembolic events during anti-TNF alpha therapy 25 or concluding that there is no correlation. 26, 27 Moreover, although an increase in anti-cardiolipin antibodies and possible thrombogenicity of anti-TNF alpha therapy have been proposed, 28 there are conflicting mechanistic data suggesting a role for elevated TNF alpha levels in the brain during CVA as partly mediating the neuronal damage, 28, 29, 30, 31, 32 thereby possibly suggesting that TNF alpha blockade may be beneficial during CVA. Elevated TNF alpha is also present in the vast majority of IBD patients, especially when the disease is active, but half of our patients were in remission when the CVA occurred, implicating a weak correlation with IBD activity. However, in the absence of population-based studies, this postulation remains at present speculative.
The limitation of the CONFER methodology should be acknowledged, as it relies on voluntary submission of cases by physicians responding to ECCO calls, which could introduce geographical and other selection biases. However, we believe this caveat is offset by the benefits of this methodology for identifying and reporting larger case series of extremely rare events, which are otherwise seldom reported other than in a single case-report format.
In conclusion, CVA affecting IBD patients treated with anti-TNF alpha agents mandates early recognition, proper work-up and specialist treatment, despite the fact that the outcome seemed to be favourable in the majority of cases in the present study. Permanent cessation of anti-TNF alpha treatment may not be universally mandatory, as continuation or resumption of the biological may be safely Continued practised in some patients. However, until further data are available, this needs to be a case-by-case decision after careful weighing of the neurological state as well as the disease activity and risk for IBD complications in the individual patient.
